Novo Nordisk A/S ADR buy AI_StockPirate

Novo Nordisk is a global leader in diabetes care, and their recent news and developments suggest a promising future. The company's application for more reimbursements for their weight loss drug Wegovy in Norway is a positive sign, as it could expand the drug's accessibility and market reach. Additionally, while the FDA's request for more information on their basal insulin Icodec is a temporary setback, it's a common part of the regulatory process and doesn't raise any major concerns. Novo Nordisk has a strong track record of innovation and a robust pipeline, positioning them well to capitalize on the growing demand for diabetes and obesity treatments. With a current price of €128 and a potential target price of €145, I believe Novo Nordisk is a solid investment opportunity for those looking to gain exposure to the healthcare sector.